| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
14.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $244.6 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
| Total People Sold |
2 |
2 |
8 |
9 |
| Total Sell Transactions |
6 |
6 |
20 |
54 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang Jane |
CMO, Hematology |
• – – |
2017-11-16 |
4 |
AS |
$85.00 |
$51,000 |
I/I |
(600) |
2,100 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-11-15 |
4 |
AS |
$79.16 |
$5,300,508 |
D/D |
(66,068) |
349,043 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-11-14 |
4 |
AS |
$79.55 |
$4,770,950 |
D/D |
(59,835) |
415,111 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2017-11-13 |
4 |
AS |
$82.79 |
$298,747 |
D/D |
(3,601) |
0 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-11-13 |
4 |
AS |
$82.67 |
$2,080,916 |
D/D |
(25,054) |
474,946 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2017-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,204 |
7,102 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2017-10-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(49,200) |
0 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
515,000 |
21,745,525 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
410,000 |
12,935,393 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2017-08-22 |
4 |
D |
$5.39 |
$151,830 |
D/D |
(28,185) |
271,815 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2017-08-11 |
4 |
B |
$71.00 |
$12,499,976 |
I/I |
176,056 |
3,476,256 |
2.25 |
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-07-12 |
4 |
AS |
$71.67 |
$1,448,704 |
D/D |
(20,000) |
0 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2017-07-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
175,682 |
4,565,794 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2017-07-10 |
4 |
S |
$71.71 |
$779,900 |
D/D |
(10,810) |
0 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-07-06 |
4 |
AS |
$60.62 |
$14,221,125 |
D/D |
(219,400) |
0 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-06-28 |
4 |
AS |
$44.82 |
$1,573,345 |
D/D |
(35,000) |
20,000 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-06-23 |
4 |
AS |
$43.85 |
$1,766,353 |
D/D |
(39,895) |
46,840 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-06-22 |
4 |
AS |
$44.06 |
$2,583,269 |
D/D |
(58,605) |
86,735 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-06-02 |
4 |
AS |
$40.00 |
$221,560 |
D/D |
(5,539) |
55,000 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-05-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
9,841 |
224,372 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-05-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
19,682 |
12,505,711 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-05-04 |
4 |
AS |
$41.01 |
$184,171 |
D/D |
(4,491) |
60,539 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-05-03 |
4 |
AS |
$40.71 |
$405,871 |
D/D |
(9,970) |
65,030 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-05-01 |
4 |
AS |
$42.02 |
$88,243 |
D/D |
(2,100) |
145,340 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-04-27 |
4 |
AS |
$40.37 |
$1,374,565 |
D/D |
(34,049) |
147,440 |
|
- |
|
527 Records found
|
|
Page 19 of 22 |
|
|
1.40 (0.86%) 
